TaxuCardium Pharmaceuticals Group Inc. reported consolidated financial results for the third quarter and nine months ended September 30, 2014. For the quarter, the company reported total product sales of nil compared with $19,200 a year ago. Loss from operations was $713,202 compared to $1,527,166 last year. Net loss was $1,441,802 compared to $1,769,005 last year. Net loss applicable to common stockholders was $1,441,802 or $0.12 per basic and diluted share compared to $1,941,866 or $0.28 per basic and diluted share last year. Non-GAAP net loss was $740,641 compared with $1,769,005 a year ago. Basic and diluted Non-GAAP net loss was $0.06 compared with $0.25 a year ago.

For the nine months, the company reported product sales of nil compared with $109,200 a year ago. Loss from operations of $3,088,949 compared to loss from operations of $5,358,770 for the same period a year ago. Net loss was $3,865,216 compared to $6,148,908 last year. Net loss applicable to common stockholders was $3,865,216 or $0.36 per basic and diluted share compared to $6,554,780 or $0.99 per basic and diluted share last year. Non-GAAP net loss was $2,656,772 compared with $6,108,158 a year ago. Basic and diluted Non-GAAP net loss was $0.25 compared with $0.93 a year ago.